FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176399372> ?p ?o ?g. }

• W3176399372 endingPage "2665" @default.
• W3176399372 startingPage "2653" @default.
• W3176399372 abstract "Neovascular age-related macular degeneration (nAMD) treatment has been revolutionized by the introduction of vascular endothelial growth factor antagonists (anti-VEGF), but the need for frequent intravitreal injections poses a heavy burden to patients and physicians. Evolving anti-VEGF therapies include longer duration agents, approaches that target multiple pathways, topical anti-VEGF agents, sustained-release, and genetic therapies. Abicipar pegol, a designed ankyrin repeat protein (DARPin), demonstrated the ability to maintain stable visual acuity with 12-week dosing, but was not approved by the FDA due to higher than usual rates of intraocular inflammation. Conbercept, a recombinant anti-VEGF fusion protein, has been approved in China, and is in Phase 3 trials globally. KSI-301 is an anti-VEGF antibody biopolymer conjugate that allowed 66% of nAMD patients to maintain at least a 6-month treatment-free interval in Phase 1b studies. OPT-302, an inhibitor of VEGF-C/D, will be tested in phase 3 studies that compare anti-VEGF-A monotherapy against combination therapy with OPT-302. Faricimab is a bispecific anti-VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN-90806 is a topical anti-VEGF agent that showed the ability to reduce injection frequency by 79% compared to ranibizumab monotherapy in a phase 1/2a trial. Sustained-release anti-VEGF therapies include the ranibizumab Port Delivery System (in phase 3 studies), GB-102 (Phase 2b), OTX-TKI (phase 1), and Durasert (preclinical). Suprachoroidal delivery of the tyrosine kinase inhibitor, axitinib, is in preclinical studies. Genetic therapies in phase 1 studies include RGX-314 and ADVM-022, which introduce a viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory, potentially serving as a one-time treatment. Further investigation is warranted for drugs and delivery systems that hope to advance visual outcomes and reduce treatment burden of nAMD." @default.
• W3176399372 created "2021-07-05" @default.
• W3176399372 creator A5006123108 @default.
• W3176399372 creator A5013509468 @default.
• W3176399372 creator A5016880766 @default.
• W3176399372 creator A5068354763 @default.
• W3176399372 creator A5078375675 @default.
• W3176399372 date "2021-06-01" @default.
• W3176399372 modified "2023-10-13" @default.
• W3176399372 title "Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration" @default.
• W3176399372 cites W12577210 @default.
• W3176399372 cites W1964119221 @default.
• W3176399372 cites W1983763042 @default.
• W3176399372 cites W1992612246 @default.
• W3176399372 cites W1992955876 @default.
• W3176399372 cites W1996971370 @default.
• W3176399372 cites W2002709518 @default.
• W3176399372 cites W2003324689 @default.
• W3176399372 cites W2004117352 @default.
• W3176399372 cites W2006652444 @default.
• W3176399372 cites W2011187017 @default.
• W3176399372 cites W2018324728 @default.
• W3176399372 cites W2028808241 @default.
• W3176399372 cites W2043873545 @default.
• W3176399372 cites W2062594120 @default.
• W3176399372 cites W2063028754 @default.
• W3176399372 cites W2075634939 @default.
• W3176399372 cites W2078326688 @default.
• W3176399372 cites W2085712747 @default.
• W3176399372 cites W2122435401 @default.
• W3176399372 cites W2124415048 @default.
• W3176399372 cites W2134161293 @default.
• W3176399372 cites W2160226180 @default.
• W3176399372 cites W2166208118 @default.
• W3176399372 cites W2171962482 @default.
• W3176399372 cites W2172453889 @default.
• W3176399372 cites W2188870890 @default.
• W3176399372 cites W2265083335 @default.
• W3176399372 cites W2462291236 @default.
• W3176399372 cites W2543150770 @default.
• W3176399372 cites W2586954607 @default.
• W3176399372 cites W2589033892 @default.
• W3176399372 cites W2647725203 @default.
• W3176399372 cites W2739373612 @default.
• W3176399372 cites W2740090310 @default.
• W3176399372 cites W2753708825 @default.
• W3176399372 cites W2761741017 @default.
• W3176399372 cites W2768578909 @default.
• W3176399372 cites W2782057573 @default.
• W3176399372 cites W2789226077 @default.
• W3176399372 cites W2884705338 @default.
• W3176399372 cites W2888207742 @default.
• W3176399372 cites W2905008032 @default.
• W3176399372 cites W2933377962 @default.
• W3176399372 cites W2936430874 @default.
• W3176399372 cites W2956665584 @default.
• W3176399372 cites W2962115070 @default.
• W3176399372 cites W2973134420 @default.
• W3176399372 cites W2981587847 @default.
• W3176399372 cites W2999772712 @default.
• W3176399372 cites W3017504588 @default.
• W3176399372 cites W3033555223 @default.
• W3176399372 cites W3036312458 @default.
• W3176399372 cites W3046457241 @default.
• W3176399372 cites W3129756804 @default.
• W3176399372 cites W4250017257 @default.
• W3176399372 cites W4361738959 @default.
• W3176399372 doi "https://doi.org/10.2147/dddt.s295223" @default.
• W3176399372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8232378" @default.
• W3176399372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34188445" @default.
• W3176399372 hasPublicationYear "2021" @default.
• W3176399372 type Work @default.
• W3176399372 sameAs 3176399372 @default.
• W3176399372 citedByCount "28" @default.
• W3176399372 countsByYear W31763993722021 @default.
• W3176399372 countsByYear W31763993722022 @default.
• W3176399372 countsByYear W31763993722023 @default.
• W3176399372 crossrefType "journal-article" @default.
• W3176399372 hasAuthorship W3176399372A5006123108 @default.
• W3176399372 hasAuthorship W3176399372A5013509468 @default.
• W3176399372 hasAuthorship W3176399372A5016880766 @default.
• W3176399372 hasAuthorship W3176399372A5068354763 @default.
• W3176399372 hasAuthorship W3176399372A5078375675 @default.
• W3176399372 hasBestOaLocation W31763993721 @default.
• W3176399372 hasConcept C118487528 @default.
• W3176399372 hasConcept C126322002 @default.
• W3176399372 hasConcept C143998085 @default.
• W3176399372 hasConcept C167734588 @default.
• W3176399372 hasConcept C2776403814 @default.
• W3176399372 hasConcept C2776694085 @default.
• W3176399372 hasConcept C2777025900 @default.
• W3176399372 hasConcept C2777288759 @default.
• W3176399372 hasConcept C2777802072 @default.
• W3176399372 hasConcept C2778749236 @default.
• W3176399372 hasConcept C2781100027 @default.
• W3176399372 hasConcept C71924100 @default.
• W3176399372 hasConcept C98274493 @default.
• W3176399372 hasConceptScore W3176399372C118487528 @default.

• next